PDF
ePub
Citation
Print
Abstract
Background
Primary aldosteronism is the most common cause of secondary hypertension in humans. Its prevalence is estimated to be 10-15% among hypertensive patients. It is also associated with insulin resistance and diabetes mellitus. The aim of our study was to compare the prevalence of primary aldosteronism in hypertensive patients with presence of diabetes mellitus.
Methods
We reviewed retrospectively the clinical records of 104 hypertensive patients for whom we also measured plasma renin activity (PRA) and plasma aldosterone concentrations (PAC).
Results
Among 104 hypertensive patients, 44 had diabetes and 60 did not. There were no significant differences in clinical characteristics between non-diabetic and diabetic patients except for age and the number of antihypertensive agents. Patients with target organ damage were more common among diabetic patients. There was no correlation between PAC and the number of target organs damaged. In addition, Four patients from the non-diabetic and two from the diabetic group had a ratio over 30 for PRA/PAC and a PAC of over 15 ng/dL. Two non-diabetic patients and one diabetic patient were found, on abdomen CT, to have an adrenal adenoma. The rest of the patients refused further tests.
References
1. Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006. 1:1039–1045.
2. Giacchetti G, Sechi LA, Rilli S, Carey RM. The reṅin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005. 16:120–126.
3. McFarlane SI, Sowers JR. Cardiovascular endocrinology l: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab. 2003. 88:516–523.
4. Campión J, Maestro B, Mata F, Dávila N, Carranza MC, Calle C. Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells. J Steroid Biochem Mol Biol. 1999. 70:211–218.
5. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vetto R, Veglio F, Mulatero P. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007. 20:855–861.
6. Perkins JM, Davis SN. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes. 2008. 15:147–152.
7. Fredersdorf S, Endemann DH, Luchner A, Heitzmann D, Ulucan C, Birner C, Schmid P, Stoelcker B, Resch M, Muders F, Riegger GA, Weil J. Increased aldosterone levels in a model of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2009. 117:15–20.
8. Sung YA, Kyung NH. Mechanism of angiotensin 2 - stimulated aldosterone secretion in adrenal glomerulosa cells of diabetic rats; normal phospholipase activity and intracellular calcium mobilization. J Korean Soc Endocrinol. 1997. 12:230–244.
9. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995. 26:869–879.
10. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, Passan DR, Williams GH, Hollenberg NK. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999. 10:2382–2391.
11. Strain WD, Chaturvedi N. The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst. 2002. 3:243–246.
12. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension. 1997. 29:723–727.
13. Park J, Kim DJ, Yang SJ, Kim SH, Park SY, Yoo HJ, Lee YJ, Kim HY, Ryu OH, Lee KW, Seo JA, Kim SG, Choi KM, Baik SH, Choi DS. Comparison of target organ damages between primary aldosteronism and essential hypertension. J Korean Soc Endocrinol. 2007. 22:11–18.
14. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003. 21:2149–2157.
15. Mantero F, Mattarello MJ, Albiger NM. Detecting and treating primary aldosteronism: primary aldosteronism. Exp Clin Endocrinol Diabetes. 2007. 115:171–174.
16. Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocr J. 2007. 54:487–495.
17. Jefic D, Mohiuddin N, Alsabbagh R, Fadanelli M, Steigerwalt S. The prevalence of primary aldosteronism in diabetic patients. J Clin Hypertens (Greenwich). 2006. 8:253–256.
18. Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, Chapman A. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care. 2007. 30:1699–1703.
19. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002. 40:897–902.
20. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens. 2008. 26:613–621.
21. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin acitivity. Clin Chem. 2005. 51:386–394.
22. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001. 37:699–705.
23. Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol. 2004. 150:329–337.
XML Download